Validated across a wide range of peer-reviewed publications

We work with forward-looking researchers to demonstrate the clinical value of our solutions to patients, clinicians and the risk-bearing payors such as health plans and accountable care organizations (ACOs) that support them.

Clinical Evidence

AstraZeneca real-world evidence study for a severe asthma treatment uses NuvoAir to monitor and assess lung function
NuvoAir resulted in high adherence, high reliability and high concordance with hospital-based spirometry in Boston Children's Hospital study
COPD members are highly engaged when supported by care coordinators in NuvoAir Virtual-First Care
Regeneron observational study used NuvoAir to monitor effects of allergen exposure on asthma patients
NuvoAir Cough app shows precision rate of 84% in detecting coughs
Improved clinical outcomes seen with long-term use of the NuvoAir Home platform
Patients and clinicians in England-wide survey report high value and trust with NuvoAir Home to detect changes in lung function and monitor lung health
Improved attendance rates and reduced hospital admission rates with virtual clinics supported by NuvoAir Home for patients with difficult asthma
Adults with severe asthma perform high quality unsupervised home spirometry with NuvoAir
High acceptability of NuvoAir home monitoring with pediatric asthma patients at Royal Brompton Hospital
Quality and high adherence to NuvoAir Home shows promise for long-term monitoring of pediatric asthma
NuvoAir supports home administration of biologics for pediatric severe asthma
NuvoAir Home respiratory platform supports remote monitoring of asthma patients
Unsupervised home spirometry with the platform is found equivalent to in-clinic spirometry
NuvoAir with unsupervised in-app coaching meets ATS/ERS repeatability criteria for both pediatric CF and bronchiectasis patients
Swedish pilot shows technology can be used at home by children with CF with postive experience of virtual clinics
Proven effective in driving virtual consultations during an 18-month patient research
Pilot Study with Göteborg, Respiratory Medicine confirms NuvoAir Platform well complements CF care
NuvoAir Reduced Booked and Urgent Face to Face Consultations in Cystic Fibrosis Patients
Pilot study with Royal Brompton Hospital suggests NuvoAir platform may improve Cystic Fibrosis outcomes

Real-World-Data from our engagements reveals great health economic outcome potential and staggering acceptance

9.4 - Acceptance of NuvoAir solution on a scale from 0 to 10

Booked
Consultations

Urgent
Consultations

Improved understanding
of their condition

Improved
medication adherence

ePS1.07 Patient experience of virtual consultations: survey results, Journal of Cystic Fibrosis Volume 19, Supplement 2, June 2020, Page s39

Our Partners

Hospitals, universities, pharma companies and CROs around the world have chosen NuvoAir as their respiratory partner. We’re proud to support the work of forward-thinking, innovative players and researchers.

Seattle Children's Hospital
Roche
HNS Royal Brompton & Harefield
Regeneron
Novartis
NHS King's College Hospital
Dartmouth-Hitchcock
InterMedCon Gmbh
University os Ioannina
Boston Children's Hospital